ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results
April 20 2018 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will host a conference call at
8:00 a.m. ET on Friday, May 4, 2018 to discuss its first quarter
operating results. Management also will provide a brief update on
the business.
Conference Call InformationTo access the live call by
phone, dial 719-325-4799; the conference ID is 2070974. The call
may also be accessed through the Investors section of the Company’s
website, www.immunogen.com. Following the webcast, a replay of the
call will be available at the same location through May 18,
2018.
About ImmunoGen, Inc.ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary ADC technology. The Company’s lead product
candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I
trial for FRα-positive platinum-resistant ovarian cancer, and is in
the Phase 1b/2 FORWARD II trial in combination regimens for
earlier-stage disease. ImmunoGen has three additional
clinical-stage product candidates, two of which are being developed
in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC
technology is also used in Roche's marketed product, Kadcyla®, and
in programs in development by Amgen, Bayer, Biotest, CytomX,
Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information
about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180420005134/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen,
Inc.Courtney O'Konek,
781-895-0600courtney.okonek@immunogen.comorFTI Consulting,
Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024